Lm::Mtb9Ag
This TB vaccine candidate comprises a live attenuated Listeria monocytogenes vector with two major virulence gene deletions and a T-cell immunity enhancing mutation (Lm ΔactA ΔinlB prfA*) that expresses nine M. tuberculosis immunoprotective proteins (Mpt64, TB10.4, ESAT-6, CFP10, Ag85B, EsxN, PPE68, EspA, and TB8.4 – four absent from BCG) from two chromosomal fusion protein expression…
Read MoreBCG::ESX-1Mmar
BCG::ESX-1Mmar is a recombinant BCG strain into which the extended region of the ESX-1-encoding genomic region of Mycobacterium marinum was integrated.
Read MoreBCGΔBCG1419c
This is a second-generation version of BCGΔBCG1419c, devoid of antibiotic markers. It is based on BCG Pasteur ATCC 35734.
Read MoreSpray Dried ID93+GLA-SE
AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.
Read MoreChAdOx1.85A+MVA85A*
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Read More